Table 1. Characteristics of skull base tumor clinical trials in the United States and abroad.
| Clinical trials (n = 71) | |
|---|---|
| Vestibular schwannoma | 11 (15.5%) |
| Sinonasal cancer | 1 (1.4%) |
| Pituitary tumor | 59 (83.1%) |
| Trials including an experimental drug | 8 (11.3%) |
| Trials including radiation | 6 (8.5%) |
| Trials including surgery | 7 (9.9%) |
| Mean enrollment | 61 |
| Median enrollment | 33 |
| NIH funded | 13 (18.5%) |
| Industry funded | 33 (46.9%) |
| Randomized | 63.9% (23/36) |
| Parallel group | 39.1% (25/64) |
| Double blind | 14.1% (9/64) |
Abbreviation: NIH, National Institutes of Health.
Note: Study design was not reported completely in every trial. Numbers in parentheses show total amount of trials reporting each variable of study design (randomization, parallel group, and double blinding).